Medicine and Health Sciences Commons^™

A Single Bout Of Vigorous Intensity Exercise Enhances The Efficacy Of Rituximab Against Human Chronic Lymphocytic Leukaemia B-Cells Ex Vivo, Harrison D. Collier-Bain, Annabelle Emery, Adam J. Causer, Frankie F. Brown, Rebecca Oliver, David Dutton, Josephine Crowe, Daniel Augustine, John Graby, Shoji Leach, Rachel Eddy, Daniela Rothschild-Rodriguez, Juliet C. Gray, Mark S. Cragg, Kirstie L. Cleary, Sally Moore, James Murray, James E. Turner, John P. Campbell

Research outputs 2022 to 2026

Chronic lymphocytic leukaemia (CLL) is characterised by the clonal proliferation and accumulation of mature B-cells and is often treated with rituximab, an anti-CD20 monoclonal antibody immunotherapy. Rituximab often fails to induce stringent disease eradication, due in part to failure of antibody-dependent cellular cytotoxicity (ADCC) which relies on natural killer (NK)-cells binding to rituximab-bound CD20 on B-cells. CLL cells are diffusely spread across lymphoid and other bodily tissues, and ADCC resistance in survival niches may be due to several factors including low NK-cell frequency and a suppressive stromal environment that promotes CLL cell survival. It is well established that exercise bouts …